Canada & Optimi Health
7 shared events · Importance 3 · Last updated Sep 23, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
Canada: Canada's regulatory environment, where ibogaine is not a controlled substance and Optimi Health has GMP infrastructure and Canada — Health Canada licensing, positions it as an advantageous base for ibogaine manufacture and supply.
Optimi Health: Optimi Health has secured ibogaine supply and is commencing development of finished drug products, positioning itself as a key supplier in the emerging psychedelic therapy market.
Jun 08, 2026 · 14 articles
Business
Canada: Canada is the country where Optimi Health manufactures its psilocybin and MDMA products at its GMP facility and from where it exports these products internationally.
Optimi Health: Optimi Health completed its third commercial shipment of psilocybin to Australia, expanding its market presence and generating recurring revenue from the sale of its psychedelic drug products for medical use.
Jun 29, 2026 · 12 articles
Business
Canada: Canada is the location of Optimi Health's GMP facility where the psilocybin products are manufactured and from where Canada — Health Canada issues export authorizations.
Optimi Health: Optimi Health completed its first export of psilocybin to the United Kingdom for a Phase 2 clinical trial, expanding its international market reach and solidifying its position as a vertically integrated GMP supplier of psychedelic drug products. It also completed a GMP production run of 5mg psilocybin capsules, with some earmarked for clinical research in the United States and Europe.
Jun 02, 2026 · 25 articles
Tech
Canada: Canada is the location for the trial sites and the regulatory jurisdiction where Optimi operates under Canada — Health Canada's framework. The trial may bolster Canada's position in psychedelic research.
Optimi Health: Optimi Health is the central entity initiating the Phase 2 trial, which represents its largest clinical commitment to date and a strategic step toward potential drug registration. The trial could enhance its pipeline and market positioning, though it carries development risks and no near-term revenue.
Sep 10, 2026 · 15 articles
Business
Canada: The country hosts Optimi's GMP-compliant manufacturing facilities and its Special Access Program provides patient access to the company's products.
Optimi Health: The company made the appointment to strengthen its clinical development capabilities ahead of planned Phase 2 psilocybin and Phase 3 MDMA trials. The move supports its pipeline but has limited near-term financial impact.
Sep 22, 2026 · 7 articles
Business
Canada: Canada is the location of Optimi Health's GMP-compliant manufacturing facilities in British Columbia and the jurisdiction of its Special Access Program, providing context for the company's operations.
Optimi Health: Optimi Health is the central entity of the event, announcing its participation in the H.C. Wainwright 28th Annual Global Investment Conference and making its presentation available on demand from September 11, 2026. The event offers the company a platform to engage investors, though no financial or clinical news was disclosed.
Sep 08, 2026 · 6 articles
Tech
Optimi Health: Optimi Health Corp. has launched new microdose psilocybin products, expanding its product range and market reach for clinical research and therapeutic programs internationally. This development is expected to positively impact the company's revenue and market position.
Jun 16, 2026 · 11 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Canada and Optimi Health interact across events, view sentiment trends, and discover connected entities.
Open Dashboard